Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
Prevail Therapeutics Inc. (PRVL) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/22/2021 8-K Resignation/termination of a director
Docs: "Agreement and Plan of Merger, by and among Parent, Purchaser and the Company (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K, as amended, filed by the Company on December 15, 2020 (File No. 001-38939))",
"Amended and Restated Certificate of Incorporation of Prevail Therapeutics Inc",
"Amended and Restated Bylaws of Prevail Therapeutics Inc"
12/15/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Agreement and Plan of Merger, by and among Prevail Therapeutics Inc., Eli Lilly and Company and Tyto Acquisition Corporation (pursuant to Item 601(b)(2) of Regulation S-K, the Company hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or exhibit to the Agreement and Plan of Merger)",
"Tender and Support Agreement, by and among Eli Lilly and Company, Tyto Acquisition Corporation, OrbiMed Private Investments VI, LP",
"Tender and Support Agreement, by and among Eli Lilly and Company, Tyto Acquisition Corporation, Pontifax (Cayman) V L.P., Pontifax (China) V L.P., Pontifax (Israel) V L.P. and Pontifax Late Stage Fund L.P",
"Tender and Support Agreement, by and among Eli Lilly and Company, Tyto Acquisition Corporation and Asa Abeliovich, M.D., Ph.D",
"Form of Contingent Value Right Agreement, by and among Eli Lilly and Company, Tyto Acquisition Corporation and a rights agent mutually agreeable to Eli Lilly and Company and Prevail Therapeutics Inc",
"Lilly Announces Agreement to Acquire Prevail Therapeutics"
11/13/2020 8-K Quarterly results
Docs: "Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson’s Disease with GBA1 Mutations"
11/12/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Frequently Asked Questions Regarding Arbitration Decision",
"Frequently Asked Questions Regarding Arbitration Decision"
11/02/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail's CEO"
09/10/2020 8-K Quarterly results
08/11/2020 8-K Quarterly results
06/17/2020 8-K Submission of Matters to a Vote of Security Holders
Docs: "FORM 8-K"
05/14/2020 8-K Quarterly results
Docs: "Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business Highlights Phase 1/2 Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Ongoing; Study Startup Activities Progressing for Phase 1/2 Trials of PR001 for Type 2 Neuronopathic Gaucher Disease and PR006 for Frontotemporal Dementia with GRN Mutations"
03/26/2020 8-K Quarterly results
03/03/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation",
"Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson's Disease with GBA1 mutations",
"Presentation dated March 2020"
01/13/2020 8-K Investor presentation
Docs: "Presentation dated January 2020",
"Presentation dated January 2020"
01/09/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Prevail Therapeutics Provides PR001 Program Update"
12/26/2019 8-K Quarterly results
11/18/2019 8-K Quarterly results
11/12/2019 8-K Quarterly results
10/08/2019 8-K Quarterly results
09/10/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Prevail Therapeutics Provides Program Update on PR001 in Parkinson's Disease with"
08/15/2019 8-K Quarterly results
08/14/2019 8-K Quarterly results
Docs: "IND Active for PR001: In May 2019, Prevail’s Investigational New Drug Application for its lead gene therapy candidate, PR001, for the treatment of Parkinson’s disease patients with a GBA1 mutation was accepted by the U.S. Food and Drug Administration and is now active. Clinical site activation is ongoing, with patient dosing on track for the fourth quarter of 2019. • Fast Track Designation Received for PR001: In July 2019, Prevail announced that the FDA granted Fast Track Designation for PR001 for the treatment of PD-GBA. • Preclinical Development of PR006 for Frontotemporal Dementia Patients with a GRN Mutation advanced: Based on pre-IND regulatory interaction with the FDA in June 2019, Prevail intends to initiate its Phase 1/2 clinical trial in FTD-GRN patients in the first..."
06/25/2019 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.0001 per share PRVL The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company ...",
"Amended and Restated Certificate of Incorporation of the Registrant",
"Amended and Restated Bylaws of the Registrant"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy